Auris Medical Holding AG | CIK:0001601936 | 3

  • Filed: 3/22/2018
  • Entity registrant name: Auris Medical Holding AG (CIK: 0001601936)
  • Generator: Workiva (WebFilings)
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1601936/000160193618000007/0001601936-18-000007-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1601936/000160193618000007/ears-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001601936
  • Open this page in separate window: Click
  • ifrs-full:DisclosureOfFinancialInstrumentsExplanatory

    Financial instruments and risk management

    The following table shows the carrying amounts of financial assets and financial liabilities:
     
     
     
     
    Financial assets
     
     
     
     
    December 31, 2017
     
    December 31, 2016
    Cash and cash equivalents
    14,973,369

     
    32,422,222

    Loans and receivables
     
     
     
    Other receivables
    79,840

     
    134,900

    Total financial assets
    15,053,209

     
    32,557,122

     
     
     
     
    Financial liabilities
     
     
     
    At amortized cost
     
     
     
    Trade and other payables
    1,200,820

     
    1,837,997

    Accrued expenses
    4,395,609

     
    4,652,033

    Loan
    10,126,406

     
    12,364,204

    At fair value through profit and loss
     
     
     
    Derivative financial instruments
    1,836,763

     
    117,132

    Total financial liabilities
    17,559,598

     
    18,971,366

     
     
     
     



    Fair values
    The carrying amount of cash and cash equivalents, other receivables, trade and other payables and accrued expenses is a reasonable approximation of their fair value due to the short term nature of these instruments. In respect of the Company’s loan which has floating rates of interest, the fair value approximates carrying value.
    Financial risk factors
    The Group’s activities expose it to a variety of financial risks: market risk, credit risk, interest rate and liquidity risk. The Group’s overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the Group’s financial performance. Management identifies, evaluates and controls financial risks. No financial derivatives have been used in 2017 and 2016 to hedge risk exposures. The Group invests its available cash in instruments with the main objectives of preserving principal, meeting liquidity needs and minimizing foreign exchange risks. The Group allocates its liquid assets to first tier Swiss or international banks.
    Liquidity risk
    The Group’s principal source of liquidity is its cash reserves which are mainly obtained through the issuance of new shares. The Group has succeeded in raising capital to fund its development activities to date and has raised funds that will allow it to meet short term development expenditures. The Company will require regular capital injections to continue its development work, which may be dependent on meeting development milestones, technical results and/or commercial success. Management monitors rolling forecasts of the Group’s liquidity requirements to ensure it has sufficient cash to meet operational needs. The ability of the Group to maintain adequate cash reserves to sustain its activities in the medium term is highly dependent on the Group’s ability to raise further funds. Consequently, the Group is exposed to continued liquidity risk.
    The table below analyses the remaining contractual maturities of financial liabilities, including estimated interest payments as of December 31, 2017 and 2016. The amounts disclosed in the table are the undiscounted cash flows:
     
    Carrying
    amount
     
    Less than 3
    months
     
    Between 3
    months and
    2 years
     
    2 years
    and later
     
    Total
    December 31, 2017
     
     
     
     
     
     
     
     
     
    Trade and other payables
    1,200,820

     
    1,200,820

     

     

     
    1,200,820

    Accrued expenses
    4,395,609

     
    4,395,609

     

     

     
    4,395,609

    Loan and borrowings
    10,126,406

     
    1,349,531

     
    9,446,716

     
    1,166,225

     
    11,962,472

    Derivative financial instruments
    1,836,763

     

     

     
    1,836,763

     
    1,836,763

    Total
    17,559,598

     
    6,945,960

     
    9,446,716

     
    3,002,988

     
    19,395,664

     
    Carrying
    amount
     
    Less than 3
    months
     
    Between 3
    months and
    2 years
     
    2 years
    and later
     
    Total
    December 31, 2016
     
     
     
     
     
     
     
     
     
    Trade and other payables
    1,837,997

     
    1,837,997

     

     

     
    1,837,997

    Accrued expenses
    4,652,033

     
    3,632,752

     
    1,019,281

     

     
    4,652,033

    Loan and borrowings
    12,364,204

     
    311,013

     
    8,725,772

     
    6,834,249

     
    15,871,034

    Derivative financial instruments
    117,132

     

     

     
    117,132

     
    117,132

    Total
    18,971,366

     
    5,781,762

     
    9,745,053

     
    6,951,381

     
    22,478,196

     
     
     
     
     
     
     
     
     
     





    Fair value measurement
     
    Financial
    assets / liabilities
    Fair values as at
    Fair value
    hierarchy
    Valuation technique(s) and key input(s)
     
     
    December 31,
    2017
    December 31,
    2016
     
    Derivative financial liabilities
     Liability
    1,836,763
     Liability
    117,132
     Level 2
    Black-Scholes option pricing model

    The share price is determined by our NASDAQ quoted-price. The strike price and maturity are coming from the contract. The volatility assumption is driven by our historic quoted share price and the risk free rate is estimated based on observable yield curves at the end of each reporting period.
     
     
     
     
     
     
     
     
     
     
    Non-cash changes
     
     
     
    01.01.2017

     
    Financing
    Cash Flows 1)
     
    Fair value
    revaluation
     
    Other
    changes 2)
     
    31.12.2017

    Derivative financial instrument
    117,132

     
    5,091,817

     
    (3,372,186
    )
     

     
    1,836,763

    Loans
    12,364,204

     
    (2,087,076
    )
     

     
    (150,722
    )
     
    10,126,406

    Total
    12,481,336

     
    3,004,741

     
    (3,372,186
    )
     
    (150,722
    )
     
    11,963,169

     
     
     
     
     
     
     
     
     
     
    1) The financing cash flows are from loan repayment and from issuance of new derivative
    2) Internal rate of return changes and fx-difference

    Credit risk
    Credit risk is managed on a Group basis. Credit risk arises from cash and cash equivalents and deposits with banks, as well as from other receivables. The Company’s policy is to invest funds in low risk investments including interest bearing deposits. Other receivables were current as of December 31, 2017 and December 31, 2016, not impaired and included only well-known counterparties.
    The Group has been holding cash and cash equivalents in the Group’s principal operating currencies (CHF, USD and EUR) with international banks of high credit rating.
    The Group’s maximum exposure to credit risk is represented by the carrying amount of each financial asset in the consolidated statement of financial position:
     
    December 31, 2017
     
    December 31, 2016
    Financial assets
     
     
     
    Cash and cash equivalents
    14,973,369

     
    32,442,222

    Other receivables
    79,840

     
    134,900

    Total
    15,053,209

     
    32,577,122

     
     
     
     

    As of December 31, 2017 and December 31, 2016 other receivables consisted of other non-current receivables from third party and deposits for rent.
    Market risk
    Currency risk
    The Group operates internationally and is exposed to foreign exchange risk arising from various exposures, primarily with respect to US Dollar and Euro. Foreign exchange risk arises from future commercial transactions, recognized assets and liabilities and net investments in foreign operations. The summary of quantitative data about the exposure of the Group’s financial assets and liabilities to currency risk was as follows:
     
    2017
     
    2016
    in CHF
    USD
     
    EUR
     
    USD
     
    EUR
    Cash and cash equivalents
    13,901,698

     
    116,942

     
    31,124,874

     
    444,075

    Trade and other payables
    (365,999
    )
     
    (426,050
    )
     
    (501,249
    )
     
    (847,892
    )
    Accrued expenses
    (1,750,752
    )
     
    (1,692,946
    )
     
    (1,031,096
    )
     
    (2,964,552
    )
    Loan and borrowings
    (10,126,406
    )
     

     
    (12,364,204
    )
     

    Derivative financial instruments
    (1,836,763
    )
     

     
    (117,132
    )
     

    Net statement of financial position exposure -asset/(liability)
    (178,222
    )
     
    (2,002,054
    )
     
    17,111,193

     
    (3,368,369
    )
     
     
     
     
     
     
     
     

    As of December 31, 2017, a 5% increase or decrease in the USD/CHF exchange rate with all other variables held constant would have resulted in a CHF 8,662 (2016: CHF 872,443) increase or decrease in the net result. Also, a 5% increase or decrease in the EUR/CHF exchange rate with all other variables held constant would have resulted in a CHF 117,320 (2016: CHF 180,595) increase or decrease in the net result.
    The Company has subsidiaries in the United States and Ireland, whose net assets are exposed to foreign currency translation risk. Due to the small size of the subsidiaries the translation risk is not significant.
    Interest rate risk

    On July 19, 2016, the Company entered into a Loan and Security Agreement for a secured term loan facility of up to $20.0 million with Hercules Capital, Inc. as administrative agent (“Hercules”) and the lenders party thereto. An initial tranche of $12.5 million was drawn on July 19, 2016, concurrently with the execution of the loan agreement. The loan matures on January 2, 2020 and bears interest at a minimum rate of 9.55% per annum, and is subject to the variability of the prime interest rate. The Company’s exposure to interest rates on financial assets and financial liabilities is resulting from loan and cash at banks. As of December 31, 2017 an increase or decrease in interest rates on financial obligations by 50 basis points with all other variables held constant would have resulted in a CHF 62,500 (2016: 28,276) increase or decrease in the net result.
    Capital risk management
    The Company and its subsidiaries are subject to capital maintenance requirements under local law in the country in which it operates. To ensure that statutory capital requirements are met, the Company monitors capital, at the entity level, on an interim basis as well as annually. From time to time the Company may take appropriate measures or propose capital increases to ensure the necessary capital remains intact.